Amarin Corp. has enrolled more than 6,000 patients in its REDUCE-IT cardiovascular outcomes study of Vascepa capsules. REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial) is a multinational, prospective, randomized, double-blind, placebo-controlled, parallel-group study taking place at over 400 clinical sites in 11 countries to evaluate the effectiveness and safety of Vascepa capsules, as an adjunct to optimized statin therapy, in reducing the incidence of first ma...